Our Co-Founder and Chief Medical AI Officer, Arturo LoAIza-Bonilla MD (
@DrArturoAI), joined the Riyadh Global Medical Biotechnology Summit (
@rgmbs) to share how agentic AI is reshaping the path from diagnosis to treatment, representing the U.S. and Massive Bio on the global stage.
The core idea: a test result only matters if it leads somewhere. Too often, biomarker data sits disconnected from the next step, whether that's a clinical trial, a specialist referral, or a treatment change. Multi-agentic AI closes that gap, coordinating testing, trial matching, and navigation while keeping physicians firmly in control of the decisions that matter.
There's a bigger system taking shape here too: when patients consent to share their journeys, that data doesn't just help them, it feeds back into building smarter models and better therapies for the patients who come next. This is the loop we're building at Massive Bio: precision care informing research, research informing drug development, and each patient's outcome making the next one's care better.
Thank you to sponsors including
@AstraZeneca,
@Novartis ,
@thermofisher,
@Roche and more for supporting this conversation on the global stage.
#PrecisionOncology #AgenticAI #RGMBS #Healthtech #AI